Amgen registers Phase 3 trial comparing subcutaneous and IV tarlatamab in relapsed ES-SCLC

This week brought one new registry entry for Amgen.

• Amgen is recruiting for "A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants With Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line Chemotherapy," known as DeLLphi-315 (NCT07778316). The trial's primary objective is to demonstrate non-inferiority in pharmacokinetic parameters of subcutaneous versus intravenous tarlatamab administration and to characterize efficacy, safety, and tolerability of the subcutaneous form in participants with relapsed extensive-stage small-cell lung cancer after platinum-based chemotherapy.¹ The study plans to enroll 400 participants (estimated)¹ and has an estimated primary completion date of 2027-09-24.